<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35801511</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-8355</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cell biology international</Title><ISOAbbreviation>Cell Biol Int</ISOAbbreviation></Journal><ArticleTitle>Potential proteomic alteration in the brain of Tg(SOD1*G93A)1Gur mice: A new pathogenesis insight of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1378</StartPage><EndPage>1398</EndPage><MedlinePgn>1378-1398</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cbin.11842</ELocationID><Abstract><AbstractText>The pathogenesis of amyotrophic lateral sclerosis (ALS) remains unclear. The recent studies have suggested that the protein abnormalities could play some important roles in ALS because several protein mutations were found in individuals with this disease. However, proteins that are currently known to be associated with ALS only explain the pathogenesis of this disease in a minority of cases, thus, further screening is needed to identify other ALS-related proteins. In this study, we systematically analyzed and compared the brain proteomic alterations between a mouse model of ALS, the Tg(SOD1*G93A)1Gur model, and wild-type mice using isobaric tags for relative and absolute quantitation (iTRAQ) as well as bioinformatics methods. The results revealed some significant up- and downregulated proteins at the different developmental stages in the ALS-like mice as well as the possibly related cellular components, molecular functions, biological processes, and pathways in the development of ALS. Our results identified some possible proteins that participate in the pathogenesis of ALS as well as the cellular components that are damaged by these proteins, we additionally identified the molecular functions, the biological processes, and the pathways of these proteins as well as the molecules that are associated with these pathways. This study represents an important preliminary investigation of the role of proteomic abnormalities in the pathogenesis of ALS, both in human patients and other animal models. We present some novel findings that may serve as a basis for further investigation of abnormal proteins that are involved in the pathogenesis of ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 International Federation for Cell Biology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>An</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, Affiliated People's Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, Affiliated People's Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Huiting</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, Affiliated People's Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Weiming</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Renshi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0313-3434</Identifier><AffiliationInfo><Affiliation>Department of Neurology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Jiangxi Provincial People's Hospital, Clinical College of Nanchang Medical College, First Affiliated Hospital of Nanchang Medical College, Affiliated People's Hospital of Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>[2014]-47</GrantID><Agency>Jiangxi Provincial Department of Science and Technology</Agency><Country/></Grant><Grant><GrantID>20142BBG70062</GrantID><Agency>Jiangxi Provincial Department of Science and Technology</Agency><Country/></Grant><Grant><GrantID>20171BAB215022</GrantID><Agency>Jiangxi Provincial Department of Science and Technology</Agency><Country/></Grant><Grant><GrantID>20192BAB</GrantID><Agency>Jiangxi Provincial Department of Science and Technology</Agency><Country/></Grant><Grant><GrantID>GJJ13198</GrantID><Agency>Education Department of Jiangxi Province</Agency><Country/></Grant><Grant><GrantID>GJJ170021</GrantID><Agency>Education Department of Jiangxi Province</Agency><Country/></Grant><Grant><GrantID>30560042</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81160161</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81360198</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>20181019</GrantID><Agency>Health and Family Planning Commission of Jiangxi Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cell Biol Int</MedlineTA><NlmUniqueID>9307129</NlmUniqueID><ISSNLinking>1065-6995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">iTRAQ</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">transgenic mice</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>8</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35801511</ArticleId><ArticleId IdType="doi">10.1002/cbin.11842</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Almad, A. A., Doreswamy, A., Gross, S. K., Richard, J.-P., Huo, Y., Haughey, N., &amp; Maragakis, N. J. (2016). Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis. GLIA, 64(7), 1154-1169. https://doi.org/10.1002/glia.22989</Citation></Reference><Reference><Citation>Amor, S., Peferoen, L. A. N., Vogel, D. Y. S., Breur, M., van der Valk, P., Baker, D., &amp; van Noort, J. M. (2014). Inflammation in neurodegenerative diseases-an update. Immunology, 142(2), 151-166. https://doi.org/10.1111/imm.12233</Citation></Reference><Reference><Citation>Andrews, G. L., Simons, B. L., Young, J. B., Hawkridge, A. M., &amp; Muddiman, D. C. (2011). Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Analytical Chemistry, 83(13), 5442-5446. https://doi.org/10.1021/ac200812d</Citation></Reference><Reference><Citation>Baralle, M., Buratti, E., &amp; Baralle, F. E. (2013). The role of TDP-43 in the pathogenesis of ALS and FTLD. Biochemical Society Transactions, 41(6), 1536-1540. https://doi.org/10.1042/BST20130186</Citation></Reference><Reference><Citation>Barmada, S. J. (2015). Linking RNA dysfunction and neurodegeneration in amyotrophic lateral sclerosis. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(2), 340-351. https://doi.org/10.1007/s13311-015-0340-3</Citation></Reference><Reference><Citation>Bendotti, C., Marino, M., Cheroni, C., Fontana, E., Crippa, V., Poletti, A., &amp; De Biasi, S. (2012). Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: Implication for protein aggregation and immune response. Progress in Neurobiology, 97(2), 101-126. https://doi.org/10.1016/j.pneurobio.2011.10.001</Citation></Reference><Reference><Citation>Blokhuis, A. M., Groen, E. J. N., Koppers, M., van den Berg, L. H., &amp; Pasterkamp, R. J. (2013). Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathologica, 125(6), 777-794. https://doi.org/10.1007/s00401-013-1125-6</Citation></Reference><Reference><Citation>Bozzo, F., Mirra, A., &amp; Carr&#xec;, M. T. (2017). Oxidative stress and mitochondrial damage in the pathogenesis of ALS: New perspectives. Neuroscience Letters, 636, 3-8. https://doi.org/10.1016/j.neulet.2016.04.065</Citation></Reference><Reference><Citation>Cairns, N. J., Lee, V. M. -Y., &amp; Trojanowski, J. Q. (2004). The cytoskeleton in neurodegenerative diseases. The Journal of Pathology, 204(4), 438-449. https://doi.org/10.1002/path.1650</Citation></Reference><Reference><Citation>Clark, J. A., Yeaman, E. J., Blizzard, C. A., Chuckowree, J. A., &amp; Dickson, T. C. (2016). A case for microtubule vulnerability in amyotrophic lateral sclerosis: altered dynamics during disease. Frontiers in Cellular Neuroscience, 10, 204. https://doi.org/10.3389/fncel.2016.00204</Citation></Reference><Reference><Citation>Colombrita, C., Onesto, E., Tiloca, C., Ticozzi, N., Silani, V., &amp; Ratti, A. (2011). RNA-binding proteins and RNA metabolism: A new scenario in the pathogenesis of amyotrophic lateral sclerosis. Archives Italiennes de Biologie, 149(1), 83-99. https://doi.org/10.4449/aib.v149i1.1261</Citation></Reference><Reference><Citation>Da Cruz, S., &amp; Cleveland, D. W. (2011). Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Current Opinion in Neurobiology, 21(6), 904-919. https://doi.org/10.1016/j.conb.2011.05.029</Citation></Reference><Reference><Citation>Dupuis, L., Pradat, P.-F., Ludolph, A. C., &amp; Loeffler, J.-P. (2011). Energy metabolism in amyotrophic lateral sclerosis. The Lancet Neurology, 10(1), 75-82. https://doi.org/10.1016/S1474-4422(10)70224-6</Citation></Reference><Reference><Citation>Furukawa, Y., &amp; Tokuda, E. (2017). Aggregation of FET proteins as a pathological change in amyotrophic lateral sclerosis. Advances in Experimental Medicine and Biology, 925, 1-12. https://doi.org/10.1007/5584_2016_32</Citation></Reference><Reference><Citation>Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., Hashemi, M., Owji, A. A., &amp; &#x141;os, M. J. (2014). Autophagy and apoptosis dysfunction in neurodegenerative disorders. Progress in Neurobiology, 112, 24-49. https://doi.org/10.1016/j.pneurobio.2013.10.004</Citation></Reference><Reference><Citation>Guerrero, E. N., Wang, H., Mitra, J., Hegde, P. M., Stowell, S. E., Liachko, N. F., Kraemer, B. C., Garruto, R. M., Rao, K. S., &amp; Hegde, M. L. (2016). TDP-43/FUS in motor neuron disease: Complexity and challenges. Progress in Neurobiology, 145-146, 78-97. https://doi.org/10.1016/j.pneurobio.2016.09.004</Citation></Reference><Reference><Citation>Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., &amp; Deng, H. X. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264(5166), 1772-1775. https://doi.org/10.1126/science.8209258</Citation></Reference><Reference><Citation>Hanson, K. A., Kim, S. H., &amp; Tibbetts, R. S. (2012). RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond. Wiley Interdisciplinary Reviews: RNA, 3(2), 265-285. https://doi.org/10.1002/wrna.111</Citation></Reference><Reference><Citation>Henriques, A., Pitzer, C., &amp; Schneider, A. (2010). Characterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease development. PLoS One, 5(11), e15445. https://doi.org/10.1371/journal.pone.0015445</Citation></Reference><Reference><Citation>Hooten, K. G., Beers, D. R., Zhao, W., &amp; Appel, S. H. (2015). Protective and toxic neuroinflammation in amyotrophic lateral sclerosis. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(2), 364-375. https://doi.org/10.1007/s13311-014-0329-3</Citation></Reference><Reference><Citation>Ince, P. G., Lowe, J., &amp; Shaw, P. J. (1998). Amyotrophic lateral sclerosis: Current issues in classification, pathogenesis and molecular pathology. Neuropathology and Applied Neurobiology, 24(2), 104-117. https://doi.org/10.1046/j.1365-2990.1998.00108.x</Citation></Reference><Reference><Citation>Irvin, C. W., Kim, R. B., &amp; Mitchell, C. S. (2015). Seeking homeostasis: Temporal trends in respiration, oxidation, and calcium in SOD1 G93A amyotrophic lateral sclerosis mice. Frontiers in Cellular Neuroscience, 9, 248. https://doi.org/10.3389/fncel.2015.00248</Citation></Reference><Reference><Citation>Julien, J. P., &amp; Beaulieu, J. M. (2000). Cytoskeletal abnormalities in amyotrophic lateral sclerosis: Beneficial or detrimental effects? Journal of the Neurological Sciences, 180(1-2), 7-14. https://doi.org/10.1016/s0022-510x(00)00422-6</Citation></Reference><Reference><Citation>Kabashi, E., &amp; Durham, H. D. (2006). Failure of protein quality control in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta, 1762(11-12), 1038-1050. https://doi.org/10.1016/j.bbadis.2006.06.006</Citation></Reference><Reference><Citation>Kamelgarn, M., Chen, J., Kuang, L., Arenas, A., Zhai, J., Zhu, H., &amp; Gal, J. (2016). Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochimica et Biophysica Acta, 1862(10), 2004-2014. https://doi.org/10.1016/j.bbadis.2016.07.015</Citation></Reference><Reference><Citation>Kanehisa, M., Limviphuvadh, V., &amp; Tanabe, M. (2010). Knowledge-based analysis of protein interaction networks in neurodegenerative diseases. In O. Alzate (Ed.), Neuroproteomics, frontiers in neuroscience. CRC Press/Taylor &amp; Francis.</Citation></Reference><Reference><Citation>Kaur, S. J., McKeown, S. R., &amp; Rashid, S. (2016). Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene, 577(2), 109-118. https://doi.org/10.1016/j.gene.2015.11.049</Citation></Reference><Reference><Citation>Kermer, P., Liman, J., Weishaupt, J. H., &amp; B&#xe4;hr, M. (2004). Neuronal apoptosis in neurodegenerative diseases: From basic research to clinical application. Neuro-degenerative diseases, 1(1), 9-19. https://doi.org/10.1159/000076665</Citation></Reference><Reference><Citation>Kim, R. B., Irvin, C. W., Tilva, K. R., &amp; Mitchell, C. S. (2015). State of the field: An informatics-based systematic review of the SOD1-G93A amyotrophic lateral sclerosis transgenic mouse model. Amyotrophic Lateral Sclerosis &amp; Frontotemporal Degeneration, 17(1-2), 1-14. https://doi.org/10.3109/21678421.2015.1047455</Citation></Reference><Reference><Citation>King, A. E., Woodhouse, A., Kirkcaldie, M. T. K., &amp; Vickers, J. C. (2016). Excitotoxicity in ALS: Overstimulation, or overreaction? Experimental Neurology, 275(Pt 1), 162-171. https://doi.org/10.1016/j.expneurol.2015.09.019</Citation></Reference><Reference><Citation>Kishikawa, H., Wu, D., &amp; Hu, G. (2008). Targeting angiogenin in therapy of amyotropic lateral sclerosis. Expert Opinion on Therapeutic Targets, 12(10), 1229-1242. https://doi.org/10.1517/14728222.12.10.1229</Citation></Reference><Reference><Citation>Kumar-Singh, S. (2011). Progranulin and TDP-43: Mechanistic links and future directions. Journal of Molecular Neuroscience, 45(3), 561-573. https://doi.org/10.1007/s12031-011-9625-0</Citation></Reference><Reference><Citation>Laferriere, F., &amp; Polymenidou, M. (2015). Advances and challenges in understanding the multifaceted pathogenesis of amyotrophic lateral sclerosis. Swiss Medical Weekly, 145, w14054. https://doi.org/10.4414/smw.2015.14054</Citation></Reference><Reference><Citation>Leal, S. S., &amp; Gomes, C. M. (2015). Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Frontiers in Cellular Neuroscience, 9, 225. https://doi.org/10.3389/fncel.2015.00225</Citation></Reference><Reference><Citation>Lee, J. K., Shin, J. H., Lee, J. E., &amp; Choi, E.-J. (2015). Role of autophagy in the pathogenesis of amyotrophic lateral sclerosis. Biochimica et Biophysica Acta, 1852(11), 2517-2524. https://doi.org/10.1016/j.bbadis.2015.08.005</Citation></Reference><Reference><Citation>Ludolph, A. C., &amp; Brettschneider, J. (2015). TDP-43 in amyotrophic lateral sclerosis - is it a prion disease? European Journal of Neurology, 22(5), 753-761. https://doi.org/10.1111/ene.12706</Citation></Reference><Reference><Citation>Ludolph, A. C., Brettschneider, J., &amp; Weishaupt, J. H. (2012). Amyotrophic lateral sclerosis. Current Opinion in Neurology, 25(5), 530-535. https://doi.org/10.1097/WCO.0b013e328356d328</Citation></Reference><Reference><Citation>Mackenzie, I. R., Rademakers, R., &amp; Neumann, M. (2010). TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. The Lancet Neurology, 9(10), 995-1007. https://doi.org/10.1016/S1474-4422(10)70195-2</Citation></Reference><Reference><Citation>Martin, L. J., &amp; Chang, Q. (2012). Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis. Molecular Neurobiology, 45(1), 30-42. https://doi.org/10.1007/s12035-011-8217-x</Citation></Reference><Reference><Citation>Maruyama, H., &amp; Kawakami, H. (2013). Optineurin and amyotrophic lateral sclerosis. Geriatrics &amp; Gerontology International, 13(3), 528-532. https://doi.org/10.1111/ggi.12022</Citation></Reference><Reference><Citation>Mori, K., Nihei, Y., Arzberger, T., Zhou, Q., Mackenzie, I. R., Hermann, A., Hanisch, F., German Consortium for Frontotemporal Lobar, D., Bavarian Brain Banking, A., Kamp, F., Nuscher, B., Orozco, D., Edbauer, D., &amp; Haass, C. (2016). Reduced hnRNPA3 increases C9orf72 repeat RNA levels and dipeptide-repeat protein deposition. EMBO Reports, 17(9), 1314-1325. https://doi.org/10.15252/embr.201541724</Citation></Reference><Reference><Citation>Muyderman, H., &amp; Chen, T. (2014). Mitochondrial dysfunction in amyotrophic lateral sclerosis-A valid pharmacological target? British Journal of Pharmacology, 171(8), 2191-2205. https://doi.org/10.1111/bph.12476</Citation></Reference><Reference><Citation>Navone, F., Genevini, P., &amp; Borgese, N. (2015). Autophagy and neurodegeneration: Insights from a cultured cell model of ALS. Cells, 4(3), 354-386. https://doi.org/10.3390/cells4030354</Citation></Reference><Reference><Citation>Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., &amp; Filip, M. (2016). Oxidative stress in neurodegenerative diseases. Molecular Neurobiology, 53(6), 4094-4125. https://doi.org/10.1007/s12035-015-9337-5</Citation></Reference><Reference><Citation>Okouchi, M., Ekshyyan, O., Maracine, M., &amp; Aw, T. Y. (2007). Neuronal apoptosis in neurodegeneration. Antioxidants &amp; Redox Signaling, 9(8), 1059-1096. https://doi.org/10.1089/ars.2007.1511</Citation></Reference><Reference><Citation>Onozato, T., Nakahara, A., Suzuki-Kouyama, E., Hineno, A., Yasude, T., Nakamura, T., Yahikozawa, H., Watanabe, M., Kayanuma, K., Makishita, H., Ohara, S., Hashimoto, T., Higuchi, K., Sakai, T., Asano, K., Hashimoto, T., Kanno, H., Nakayama, J., &amp; Oyanagi, K. (2016). Axonal TDP-43 aggregates in sporadic amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 42(6), 561-572. https://doi.org/10.1111/nan.12310</Citation></Reference><Reference><Citation>Parakh, S., &amp; Atkin, J. D. (2016). Protein folding alterations in amyotrophic lateral sclerosis. Brain Research, 1648(Pt B), 633-649. https://doi.org/10.1016/j.brainres.2016.04.010</Citation></Reference><Reference><Citation>Perri, E. R., Thomas, C. J., Parakh, S., Spencer, D. M., &amp; Atkin, J. D. (2015). The unfolded protein response and the role of protein disulfide isomerase in neurodegeneration. Frontiers in Cell and Developmental Biology, 3, 80. https://doi.org/10.3389/fcell.2015.00080</Citation></Reference><Reference><Citation>Peters, O. M., Ghasemi, M., &amp; Brown, R. H. (2015). Emerging mechanisms of molecular pathology in ALS. The Journal of Clinical Investigation, 125(5), 1767-1779. https://doi.org/10.1172/JCI71601</Citation></Reference><Reference><Citation>Pfohl, S. R., Halicek, M. T., &amp; Mitchell, C. S. (2015). Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A meta-analysis. Journal of Neuromuscular Diseases, 2(2), 137-150. https://doi.org/10.3233/JND-140068</Citation></Reference><Reference><Citation>Prpar Mihevc, S., Baralle, M., Buratti, E., &amp; Rogelj, B. (2016). TDP-43 aggregation mirrors TDP-43 knockdown, affecting the expression levels of a common set of proteins. Scientific Reports, 6, 33996. https://doi.org/10.1038/srep33996</Citation></Reference><Reference><Citation>Ratti, A., &amp; Buratti, E. (2016). Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins. Journal of Neurochemistry, 138(Suppl 1), 95-111. https://doi.org/10.1111/jnc.13625</Citation></Reference><Reference><Citation>Redler, R. L., &amp; Dokholyan, N. V. (2012). The complex molecular biology of amyotrophic lateral sclerosis (ALS). Progress in Molecular Biology and Translational Science, 107, 215-262. https://doi.org/10.1016/B978-0-12-385883-2.00002-3</Citation></Reference><Reference><Citation>Robertson, J., Kriz, J., Nguyen, M. D., &amp; Julien, J.-P. (2002). Pathways to motor neuron degeneration in transgenic mouse models. Biochimie, 84(11), 1151-1160. https://doi.org/10.1016/s0300-9084(02)00025-1</Citation></Reference><Reference><Citation>Rohrer, J. D., Isaacs, A. M., Mizielinska, S., Mead, S., Lashley, T., Wray, S., Sidle, K., Fratta, P., Orrell, R. W., Hardy, J., Holton, J., Revesz, T., Rossor, M. N., &amp; Warren, J. D. (2015). C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. The Lancet. Neurology, 14(3), 291-301. https://doi.org/10.1016/S1474-4422(14)70233-9</Citation></Reference><Reference><Citation>Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., &amp; Deng, H. X. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature, 362(6415), 59-62. https://doi.org/10.1038/362059a0</Citation></Reference><Reference><Citation>Ruegsegger, C., &amp; Saxena, S. (2016). Proteostasis impairment in ALS. Brain Research, 1648(Pt B), 571-579. https://doi.org/10.1016/j.brainres.2016.03.032</Citation></Reference><Reference><Citation>Sathasivam, S., &amp; Shaw, P. J. (2005). Apoptosis in amyotrophic lateral sclerosis-What is the evidence? The Lancet Neurology, 4(8), 500-509. https://doi.org/10.1016/S1474-4422(05)70142-3</Citation></Reference><Reference><Citation>Scotter, E. L., Chen, H.-J., &amp; Shaw, C. E. (2015). TDP-43 proteinopathy and ALS: Insights into disease mechanisms and therapeutic targets. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(2), 352-363. https://doi.org/10.1007/s13311-015-0338-x</Citation></Reference><Reference><Citation>Strong, M. J. (2003). The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacology &amp; Therapeutics, 98(3), 379-414. https://doi.org/10.1016/s0163-7258(03)00040-8</Citation></Reference><Reference><Citation>Vehvil&#xe4;inen, P., Koistinaho, J., &amp; Gundars, G. (2014). Mechanisms of mutant SOD1 induced mitochondrial toxicity in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 8, 126. https://doi.org/10.3389/fncel.2014.00126</Citation></Reference><Reference><Citation>Xiao, S., MacNair, L., McLean, J., McGoldrick, P., McKeever, P., Soleimani, S., Keith, J., Zinman, L., Rogaeva, E., &amp; Robertson, J. (2016). C9orf72 isoforms in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Brain Research, 1647, 43-49. https://doi.org/10.1016/j.brainres.2016.04.062</Citation></Reference><Reference><Citation>Zeineddine, R., &amp; Yerbury, J. J. (2015). The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. Frontiers in Physiology, 6, 277. https://doi.org/10.3389/fphys.2015.00277</Citation></Reference><Reference><Citation>Zhang, J., Huang, P., Wu, C., Liang, H., Li, Y., Zhu, L., Lu, Y., Tang, C., &amp; Xu, R. (2018). Preliminary observation about alteration of proteins and their potential functions in spinal cord of SOD1 G93A transgenic mice. International Journal of Biological Sciences, 14(10), 1306-1320. https://doi.org/10.7150/ijbs.26829</Citation></Reference><Reference><Citation>Zhou, Y., Lu, Y., Fang, X., Zhang, J., Li, J., Li, S., Deng, X., Yu, Y., &amp; Xu, R. (2015). An astrocyte regenerative response from vimentin-containing cells in the spinal cord of amyotrophic lateral sclerosis's disease-like transgenic (G93A SOD1) mice. Neuro-degenerative diseases, 15(1), 1-12. https://doi.org/10.1159/000369466</Citation></Reference><Reference><Citation>Zhou, Z.-D., Saw, W.-T., &amp; Tan, E.-K. (2017). Mitochondrial CHCHD-containing proteins: physiologic functions and link with neurodegenerative diseases. Molecular Neurobiology, 54(7), 5534-5546. https://doi.org/10.1007/s12035-016-0099-5</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>